CURRICULUM VITAE Gerald W. Dorn II, M.D

CURRICULUM VITAE

Gerald W. Dorn II, M.D.

DATE UPDATED: September 16, 2019

Philip and Sima K. Needleman Professor of Medicine

Associate Chair for Translational Research

Director, Center for Pharmacogenomics

Washington University School of Medicine

Box 8220, 660 South Euclid Avenue

St. Louis, MO 63110 USA

Phone: 314 362-4892

FAX: 314 362-8844

Phone: 314 362-4892 (office) 513 532-0812 (cell)

email: [email protected]

President and Founder

Mitochondria in Motion, Inc.

Suite 216, 4340 Duncan Avenue

St. Louis, MO 63110 USA

email: [email protected]

PERSONAL DATA

Birthdate: August 7, 1958; Monterey, CA

Marital Status: Married; Deborah Ann Hauger, M.D., FACC

Children: Lisa Elizabeth Dorn; DOB: December 27, 1992

Home Address: 4440 Lindell Blvd, #1202 St. Louis, MO 63108

EDUCATION

Year Degree Institution

1977 B.S. Biology Lander College, Greenwood, SC

1981 M.D. Medical University of South Carolina, Charleston, SC

POST-GRADUATE TRAINING

Year Position Institution

1981-1982 Intern in Internal Medical University of South Carolina

Medicine Charleston, SC

1982-1984 Resident in Internal Medical University of South Carolina

Medicine Charleston, SC

1984-1985 Fellow in Pharmacology Medical University of South Carolina

Charleston, SC

1985-1988 Fellow in Cardiology Medical University of South Carolina

Charleston, SC

Gerald W. Dorn II, MD 2

2

ACADEMIC APPOINTMENTS

University of Texas Health Science Center, San Antonio, TX

1988-1990 Assistant Professor Department of Medicine

1989-1990 Director Cardiac Catheterization Laboratory

Audie L. Murphy Memorial Veterans Hospital

University of Cincinnati

1990-1993 Assistant Professor Department of Medicine

Department of Pharmacology & Cell Biophysics

1993-1999 Associate Professor Department of Medicine

with Tenure Department of Pharmacology & Cell Biophysics

1995-1998 Director Cardiovascular Fellowship Training Program

Division of Cardiology

1995-1998 Director Cardiac Catheterization Laboratory

Cincinnati Veterans Administration Medical Center

1998-1999 Director Cardiopulmonary Molecular Pharmacology Program

1999-2008 Professor Department of Medicine

1999-2004 Division Director Division of Cardiology

2003-2004 Director Heart and Vascular Center

2003-2005 Associate Dean for College of Medicine

Cardiovascular Services

2005-2008 Director Center for Molecular Cardiovascular Research

2005-2008 Professor Department of Pediatrics

Washington University School of Medicine

2008-present Philip and Sima K Needleman Professor

Associate Chair for Department of Internal Medicine

Translational Research

2008-present Director Center for Pharmacogenomics

LICENSURE AND CERTIFICATION

Year Institution or State

1982-2017 South Carolina License #10907

1984 American Board of Internal Medicine

1987 American Board of Internal Medicine Subspecialty of Cardiovascular Disease

1988-2018 Texas License #H4904

1990 Ohio License #35-06-0148

2008 Missouri License #2008011532


3

PROFESSIONAL MEMBERSHIPS

Association of American Physicians

American Society for Clinical Investigation

Alpha Omega Alpha

American College of Cardiology, Fellow

American Heart Association, Fellow, Council on Circulation

American Clinical and Climatological Association

Heart Failure Society of America

International Society for Heart Research

HONORS AND AWARDS

1970 Eagle Scout, Boy Scouts of America Troop 234, Point Mugu, Calif.

1974-1977 Patterson Pre-Medical Scholar, Lander Fellow

1976-1977 Alpha Chi Honor Society

1984 M.U.S.C. Institutional Research Fellowship, National Research Service Award

1989 Lyndon Baines Johnson Research Award, AHA, Texas Affiliate

1992-1997 Established Investigator of the American Heart Association

1995 American Heart Association Council on Circulation Cardiovascular Prize

1998 American Society for Clinical Investigation

1999 Plenary Speaker, American Heart Association 72nd Scientific Sessions

2000-2003 Mable Stonehill Chair in Medicine

2000-2006 ASCI Institutional Representative, University of Cincinnati

2002 Alpha Omega Alpha Honor Society

2003-2008 Hanna Chair in Cardiology, University of Cincinnati

2006 Gordon Wilson Lecturer, American Clinical and Climatological Association

2009 Association of American Physicians

2009-present Philip and Sima K. Needleman Professor

2010 Co-Chair, AHA Basic Cardiovascular Sciences Annual meeting

2010 3rd Annual John Ross, Jr., MD Lecture in Cardiology, UCSD

2010 Ralph Major Lecture in Internal Medicine, Kansas University

2011 Speaker, Excellence in Basic Science, 15th Annual HFSA Scientific Meeting

2011 Chair, Myocardial Ischemia and Metabolism Study Section, NHLBI

2011 Thomas W. Smith Memorial Lecture, AHA Scientific Sessions 2011

2013 Plenary Speaker, American Heart Association Scientific Sessions 2013

2014 Invited mentor, Cardiac Regulatory Mechanisms Gordon Research Seminar

2014 Distinguished Scientist Award of the American Heart Association

2014 “Best manuscript award” Song, et al, Circulation Research 2014

2015 Co-Chair, Keystone meeting on Mitochondria, Metabolism, and Heart Failure

2015 Keith Reimer Distinguished Lecturer, International Society Heart Research 2015

2016 John Foerster Distinguished Lecturer, University of Manitoba Institute of

Cardiovascular Sciences

2017 Keynote Lecture, Sarnoff Cardiovascular Research Foundation 37th annual

scientific meeting, Boston MA

2017 Keynote Lecture, EMBO workshop “Mitochondrial Quality Control”, Xi’an,

China.

2019 Harrington Scholar-Innovator awardee.

2019 Keynote Speaker, 3rd JCS Forum on Basic Cardiovascular Research, Tokyo Japan


4

EDITORIAL BOARD MEMBERSHIP

Science, Board of Reviewing Editors 2011-present

Physiological Reviews 2010-2019

Circulation Research 1996-2014

Circulation Research, Board of Consulting Editors 2014-2019

Current Opinion in Physiology 2018-present

Circulation 1994-2015

Journal of Clinical Investigation 2008-2011

Journal of Biological Chemistry 2001-2006

RESEARCH ADVISORY COMMITTEES (2000-present)

Abstract Reviewer, American Heart Association National Scientific Meeting (1999-present)

Member, NIH CVA/ CCHF Study Section (2000-2004)

Member, NIH Site Visit for University of Colorado GCRC Renewal (2001)

Member, NIH PPG Special Review Committee “Genomic Studies of Cardiac Remodeling and Failure”

NHLBI (2002)

Member, Scientific Advisory Panel, Donald W. Reynolds Foundation Cardiovascular Clinical Research

Programs (2002-2003)

Member, Scientific Committee, The La Jolla-Rome-Yamaguchi Research Conferences on Cardiac

Function (2002-2005)

Member, NIH PPG Special Review Committee “Genomic Studies of Cardiac Remodeling and Failure”

NHLBI (2003)

Chairman, NIH Special Emphasis Panel “Cardiac Adrenergic Receptors in Hypertrophy” (2004)

Member, NIH Special Emphasis Panel “Extramural Loan Repayment Program for Clinical and Pediatric

Researchers” NHLBI (2005)

Member, NIH PPG Special Review Committee, Longevity and Stress Resistance, NIA (2005)

Ad Hoc Reviewer, NIH Cardiac Hypertrophy and Heart Failure Study Section (2005)

Member, NIH PPG Review Committee "Genesis and Treatment of Heart Failure in the Young" (2005)

NHLBI Strategic Planning Group (Level 1), Heart Failure and Cardiomyopathy (2006)

Member, NIH PPG Special Review Committee, Longevity and Stress Resistance, NIA (2006)

Member, NIH PPG Review Committee "Genesis and Treatment of Heart Failure in the Young" (2006)

Temporary Member, NIH K99/R00 Mentored Scientist Award (2006)

Temporary Member, NIH K99/R00 Mentored Scientist Award (2007)

Signaling in Hypertrophy and Failure Interest Group Program Committee, ISHR (2009-2010)

Reviewer, Norman Hackerman Advanced Research Program, Texas Higher Education Board (2010)

NHLBI/ORD workshop: “Strategic Planning for Pulmonary Vascular Disease Research (2010)

Member, NHLBI Myocardial Ischemia and Metabolism Study Section (2009-2012)

Member, AHA Cardiovascular Genome-Phenome Studies Advisory Panel (2014)

Co-Chair, AHA Cardiovascular Genome-Phenome Studies Review Committee (2014)

Temporary Member, NIA Cellular Mechanisms in Aging and Development Study Section (2015)

Member, NIH Transformative R01 (TR01) Study Section (2015-2017)

Member, NHLBI Outstanding investigator award (R35) Study Section (2017, 2018)


5

DISSERTATION COMMITTEES

Name Department Years

Haesun Kim Pathology 1993-1996

Brian Oliver Pathology/Medicine 1997-1998

Nicole Tepe Pharmacology and Cell Biophysics 1997-2000

Mark Williams Pharmacology and Cell Biophysics 1997-2000

Qiu-Jing Song (Co-Chair) Pharmacology and Cell Biophysics 2001-2004

Kimberly Gregory Pharmacology and Cell Biophysics 2001-2005

Bryan Mitton (Co-Chair) Pharmacology and Cell Biophysics 2004-2007

Theresa Okeyo-Owuor Div of Biology & Biomedical Sciences 2011-2013

Maria Trissal Div of Biology & Biomedical Sciences 2012-2014

Moshi Song (Chair) Div of Biology & Biomedical Sciences 2013-2016

Rong Zeng Div of Biology & Biomedical Sciences 2015-2016

Anna Ballard Div of Biology & Biomedical Sciences 2016-

GRADUATE QUALIFYING COMMITTEES

Vivek Kadambi Pharmacology and Cell Biophysics 1994

Saadia Ahmed Pharmacology and Cell Biophysics 1994

Metiner Tosun Pharmacology and Cell Biophysics 1995

Sheryl Koch Pharmacology and Cell Biophysics 1995

Nicole Tepe Pharmacology and Cell Biophysics 1997

UNDERGRADUATE THESIS EVALUATIONS

Xin Paul Wei Harvard University Program in Life Sciences

PROMOTIONS AND TENURE COMMITTEES

Ronglih Liao, PhD Harvard Medical School


6

OTHER COMMITTEES/LEADERSHIP POSITIONS


Member, College of Medicine Space Committee (2000-2001)

Member, Health Alliance of Greater Cincinnati Cardiovascular Service Line Committee (2000-2003)

Director, Human Gene Identification, Expression and Analysis (HuGe IdEA) initiative (2000-2004)

Chair, College of Medicine Cardiopulmonary Millennium Project Planning Committee (2000)

Member, College of Medicine Dean’s Clinical Council (2002-2004)

Washington University

Member, Institute for Clinical and Translational Sciences Executive Committee (2008-2016)

Chair, Center for Pharmacogenomics Advisory Committee (2008)

Distinguished Investigator Award Selection Committee (2009-2011)

National Organizations

Program Committee, Heart Failure Society of America (2002-2004)

Publications Committee, Heart Failure Society of America (2009-2011)

Board of Directors Member at Large, the Society for Translational Science (2010-2012)

Program Co-Chair for Genetics, American Heart Association Committee on Scientific Sessions Program

(CSSP) (2011, 2013)

Fall Program Committee Chair (2012-2015), AHA Council on Basic Cardiovascular Sciences

Katz Award Committee (2013-present), AHA Council on Basic Cardiovascular Sciences

Committee Vice-Chair (2013-2015), AHA BCVS Committee for Scientific Sessions Planning

Committee Co-Chair (2013-2015), CSSP Leadership committee, AHA Council on BCVS

AHA BCVS Council Leadership Committee (2015-2017)


7

POSTDOCTORAL TRAINEES


Safdar Ali, MD 1992-1994

Drew D'Angelo, PhD 1993-1997

John Collins, MD 1993-1994

Karamchand Paul, MD 1994-1996

William Houser, MD 1994-1996

Jacob Cheu, PhD 1995

Yoshihito Sakata, MD, PhD 1996-1997

Guangyu Wu, PhD 1999-2001

Tsuyoshi Toyokawa, MD 1999-2001

Harvey Hahn, MD 1999-2000

Thomas Barrett, PhD 2000-2001

Martin Yussman, MD 2000-2002

Faisal Syed, M.D. 2002-2003

Anita Galvez, PhD 2003-2006

Scot Matkovich, PhD 2005-2010

Washington University in St. Louis

Yun Chen, PhD 2009-2013

Casey Jowdy, PhD 2010-2011

Peter Hecker, PhD 2012-2013

Guohua Gong, PhD 2013-2015

Julie Fleischer, MD 2015-2016

Agostinho Rocha, PhD 2016-2018

Antonietta Franco, PhD 2016-2019

Xiawei Dang, PhD 2018-present

Jiajia Li, PhD 2018-present


8

MENTOR GRANT AWARDS

American Heart Association Fellowship Award. "Characterization of Promoter Elements which

Regulate the Thromboxane Receptor" Drew D. D'Angelo, Ph.D. Direct costs: $25,000. 94-95.

American Heart Association Fellowship Award. "Phosphorylation and Desensitization of

Thromboxane Receptors" William A. Houser, M.D. Direct costs: $30,000. 7/1/95-6/30/96.

American Heart Association Boots Award. "Structural and Functional Characterization of Human

Thromboxane Receptor Gene" Recipient - Drew D. D'Angelo, Ph.D. Direct costs: $25,000. 1995

American Heart Association Fellowship Award. “Interaction of Aids and Cocaine on Force

Interval Behavior and Beta Adrenergic Receptor Responsiveness” Harvey S. Hahn, M.D. Direct costs:

$30,000. 7/1/99-6/30/99.

National Institutes of Health. 5T32 HL07382-25 - “Training in Cardiovascular Biology” (Arnold

Schwartz, PI) Martin G. Yussman, M.D. Direct costs: $46,139. 7/1/01-6/30/02.

American Heart Association Fellowship Award. 0225236B - “Mitochondrial Death Protein, Nix,

in Apoptotic Cardiomyopathy” Faisal Syed, M.D. Direct costs: $30,000. 7/1/02-6/30/03.

National Institutes of Health. K08 KL71939 – “Protein Kinase C as a Determinant of Cardiac

Adrenergic Response” Harvey Hahn, M.D. Direct costs: $629,937. 02/01/04-01/31/09.

American Heart Association Predoctoral Fellowship Award. “Mitochondrial dynamics, quality

control, and cardiac homeostasis.” Moshi Song. Direct costs: $52,000. 1/1/14-12/31-15.

McDonnell Center for Cellular and Molecular Neurobiology Fellowship Award. “Small molecules

for therapeutic targeting of mitofusins in neurodegenerative disease.” Antonietta Franco, PhD. Direct

costs: $30,000. 7/1/17-6/30/18.


9

MENTOR RESEARCH AWARDS

Harvey Hahn MD, Third place, Protein Kinase C DeterminesIn Vivo Myocardial -Adrenergic

Responsiveness. AstraZeneca Young Investigator Competition, San Francisco, Ca, 2002.

Abhinav Diwan MD, First place, Junior Faculty Basic Science Research. Nix, a Bcl2 Protein, is

Essential for Maintenance of Cardiomyocyte Calcium Stores and for Apoptosis During Erythroblast

Maturation. Northwestern Cardiovascular Young Investigator's Forum, Chicago, Il, 2006.

Faisal Syed MD, Co-winner, Samuel A. Levine Young Clinical Investigator Award, Genetic -

blocakde: A G-protein Coupled Receptor Kinase-5 Polymorphism that Inhibits -adrenoreceptor

Signaling is Protective in Heart Failure. American Heart Association National Meetings, 2006.

Abhinav Diwan MD, Finalist, Louis N and Arnold M Katz Basic Science Research Prize for

Young Investigators, Nix in the Heart: Regulation of Developmental Apoptosis and Sarcoplasmic

Reticular Calcium Stores Explains its Functional Diversity. American Heart Association National

Meetings, 2006.

Yun Chen, PhD, Late Breaking Basic Science (oral), A Parkin-Mitofusin Interaction Directs

Cardiac Mitochondrial Culling Independent of Mitochondrial Fusion. AHA Scientific Sessions, 2011.

Moshi Song, NHLBI Scholar, Hypertrophic Cardiomyopathy Caused by a Rare Mitofusin 2

Mutation. Keystone Symposium on Cardiac Remodeling, Signaling, Matrix and Heart Function, 2013.

Yun Chen, PhD, Late Breaking Basic Science (Poster), Aggravation of Mitophagic

Cardiomyopathy by Highly Expressed Mitochondrial Catalase Reveals the Essential Function of

Mitochondrial-generated Ros in Mitophagy. AHA Scientific Sessions, 2013.

Moshi Song, Late Breaking Basic Science (Oral), Fulminant Lethal Cardiomyopathy Reveals

Essential Roles of Organelle Fission/Fusion in Cardiomyocyte Mitochondrial Regeneration. AHA

Scientific Sessions, 2013.

Moshi Song, 2015 Barbara Jakschik Awardee for Washington University Division of Biological

and Biomedical Sciences outstanding female graduate student whose thesis focused on the area of

metabolic regulation.

Moshi Song, 2016 Spencer T. and Ann W. Olin Fellow recognized for “past achievement and the

promise of a distinguished career in the biomedical sciences”; an Olin Fellowship is the highest award

accorded a doctoral student by Washington University in St. Louis.


10

CURRENT GRANT SUPPORT

NIH R35 HL135736 NHLBI Outstanding investigator award -

The mitochondrial dynamism/fitness/biogenesis interactome in cardiac disease.

PI – Gerald W. Dorn II. Total Costs: $6,405,000 1/1/2017-12/31/2023.

Muscular Dystrophy Association MDA628906 Research Grant -

Mitofusin agonists to treat Charcot-Marie-Tooth Disease.

PI- Gerald W Dorn II. Total Costs: $267,942 8/1/2019-7/31/2021

NIH R41 NS113642 NINDS STTR Phase I –

Mitofusin agonists to treat neurodegenerative disease.

PI – Gerald W Dorn II. Total Costs: $452,121 11/1/2019-10/31/2021

PENDING GRANT SUPPORT

NIH R41 NS115184 NINDS STTR Phase I –

Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

PI – Gerald W Dorn II. Total Costs: $237,747 Pending (score 14)

NIH U44 NS116889 Blueprint Neurotherapeutics Network: Small Molecule Drug Discovery

Mitofusin agonists to treat Charcot-Marie-Tooth disease Type 2A

PI – Sriram Devanathan; co-PI – Gerald W Dorn II. Total Costs: $3,499,091

PREVIOUS NIH GRANT SUPPORT

R01 HL128071 – Linking cell death and mitochondrial quality control mechanisms in heart disease.

Co-PIs – Gerald W. Dorn II and Richard N. Kitsis. Total Costs: $2,612,690 2015-2019.

R01 HL 128441 – Molecular orchestration of mitochondrial fitness via replacement or repair

PI - Gerald W. Dorn II. Total Costs: $1,525,000 04/01/2016-03/31/2020 (relinquished for R35)

R01 HL059888 – Mitochondrial Fusion Factors and Cardiomyopathy.

PI - Gerald W. Dorn II. Total Costs: $1,881,760 08/13/2013 – 05/31/2018 (relinquished R35).

R01HL087871– G-Protein-Dependent and –Independent Kinase Signaling in Cardiac Hypertrophy

PI - Gerald W. Dorn II. Total Costs: $2,348,808 12/01/2012 – 1/31/2017 (relinquished for R35).

R01 HL108943 – MicroRNA Targeting in Heart Failure.

PI - Gerald W. Dorn II. Total Costs: $1,520,000 12/15/2011 – 11/30/2015.

R21 HL 107276 – Mitochondrial Manipulation and Analysis in Drosophila Hearts.

PI - Gerald W. Dorn II. Total Costs: $418,000 8/01/2011 – 4/30/2013.

R01 HL080008 - Calpains as Mediators of Cardiac Ischemic Injury.

PI - Gerald W. Dorn II. Total Costs: $1,863,311 8/01/2006- 7/31/2011.

RC2 HL 102222 – CTRIP: Genetic Testing to Individualize Management of Common Heart Diseases.

PI - Gerald W. Dorn II. Total Costs: $1,905,001 9/01/2010 – 8/31/2011.

P50 HL 077101 – Genetic and Molecular Signaling in Heart Failure.

PI - Gerald W. Dorn II. Total Costs $20,471,934 01/01/2005 – 12/31/2009

R01 HL 069779 – Rab GTPase Protein Transport in Heart Disease.

PI - Gerald W. Dorn II. Total Costs $1,264,005 06/06/2002 – 03/31/2007.

R01 HL 058010 – Phospholipase C and Cardiac Hypertrophy.

PI - Gerald W. Dorn II. 08/15/1998 – 07/31/2006.

P50 HL 052318 – Specialized Center of Research in Heart Failure.


R01 HL 049267 – Megakaryocyte Development and Coronary Disease.


11



12

SCIENTIFIC PUBLICATIONS:

1. Dorn GW II, Baldwin JG Jr. Rapid development of myeloma in a patient with Hodgkin's disease.

J SC Med Assoc 80:599-600, 1984.

2. Dorn GW II, Sens D, Chaikhouni A, Mais D, Halushka PV. Cultured human vascular smooth

muscle cells with functional thromboxane A2 receptors: Measurement of U46619-induced 45Calcium efflux. Circ Res 60:952-956, 1987.

3. Dorn GW II, Burch RM, Kochel PJ, Mais DE, Halushka PV. Decrease in agonist affinity for

human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived

supernatant. Biochem Pharmacol 36:1913-1917, 1987.

4. Dorn GW II, Donner R, Assey ME, Spann JF Jr, Wiles HB, Carabello BA. Alterations in left

ventricular geometry, wall stress and ejection performance after correction of congenital aortic

stenosis. Circulation 78:1358-1364, 1988.

5. Leman RB, Spinale FG, Dorn GW II, Cooper G, Spann JF Jr, Gillette PC, Carabello BA.

Supernormal ejection performance is isolated to the ipsilateral congenitally pressure-overloaded

ventricle. J Am Coll Cardiol 13:1314-1319, 1989.

6. Dorn GW II, Gertler AS, Gordon L, Usher BW, Hendrix GH. Left ventricular dysfunction in

symptomatic mitral valve prolapse. Chest 95:370-373, 1989.

7. Dorn GW II. Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes:

A radioligand binding study of human platelets. J Clin Invest 84:1883-1891, 1989.

8. Dorn GW II, DeJesus A. Binding of an [125I] labelled thromboxane A2 prostaglandin H2 receptor

agonist to baboon platelets. Prostaglandins 38:645-653, 1989.

9. Dorn GW II. Isoelectric and mass characterization of human platelet thromboxane A2

prostaglandin H2 receptors. Biochem Biophys Res Commun 163:183-188, 1989.

10. Dorn GW II, Liel N, Trask JL, Mais DE, Assey ME, Halushka PV. Increased platelet

thromboxane A2/prostaglandin H2 receptors in patients with acute myocardial infarction.

Circulation 81:212-218, 1990.

11. Dorn GW II. Cyclic oxidation-reduction reactions regulate thromboxane A2/prostaglandin H2

receptor number and affinity in human platelet membranes. J Biol Chem 265:4240-4246, 1990.

12. Dorn GW II, DeJesus A. Human platelet aggregation and shape change are coupled to separate

thromboxane A2-prostaglandin H2 receptors. Am J Physiol 260:H327-H334, 1991.

13. Dorn GW II. Tissue- and species-specific differences in ligand binding to thromboxane A2

receptors. Am J Physiol 261:R145-R153, 1991.

14. Dorn GW II. Mechanism for homologous downregulation of thromboxane A2 receptors in

cultured human chronic myelogenous leukemia (K562) cells. J Pharmacol Exp Ther

259:228-234, 1991.

15. Jones CL, Witte DP, Feller MJ, Fugman DA, Dorn GW II, Lieberman MA. Response of a human

megakaryocytic cell line to thrombin: Increase in intracellular free calcium and mitogen release.

Biochim Biophys Acta 1136:272-282, 1992.

16. Dorn GW II, Becker MW. Growth factors downregulate vascular smooth muscle thromboxane

receptors independent of cell growth. Am J Physiol 262:C927-C933, 1992.

17. Dorn GW II. Regulation of response to thromboxane A2 in CHRF-288 megakaryocytic cells.

Am J Physiol 262:C991-C999, 1992.

18. Dorn GW II, Davis MG. Differential megakaryocytic desensitization to platelet agonists. Am J

Physiol 263:C864-C872, 1992.


13

SCIENTIFIC PUBLICATIONS (cont.)

19. Dorn GW II, Becker MW, Davis MG. Dissociation of the contractile and hypertrophic effects of

vasoconstrictor prostanoids in vascular smooth muscle. J Biol Chem 267:24897-24905, 1992.

20. Dorn GW II, Davis MG. Thrombin, but not thromboxane, stimulates megakaryocytic

differentiation in human megakaryoblastic leukemia cells. J Pharmacol Exp Ther 262:1242-1247,

1992.

21. Dorn GW II, Becker MW. Thromboxane A2 stimulated signal transduction in vascular smooth

muscle. J Pharmacol Exp Ther 265:447-456, 1993.

22. Ali S, Davis MG, Becker MW, Dorn GW II. Thromboxane A2 stimulates vascular smooth

muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast

growth factor. J Biol Chem 268:17397-17403, 1993.

23. Williams SP, Dorn GW II, Rapoport RM. Prostaglandin I2 mediates contraction and relaxation of

vascular smooth muscle. Am J Physiol 267:H796-H803, 1994.

24. Dorn GW II, Davis MG, D'Angelo DD. Gene expression during phorbol ester-induced

differentiation of cultured human megakaryoblastic cells. Am J Physiol 266:C1231-1239, 1994.

25. Dorn GW II, Robbins J, Ball N, Walsh RA. Myosin heavy chain regulation and myocyte

contractile depression after LV hypertrophy in aortic-banded mice. Am J Physiol 267:H400-

H405, 1994.

26. Davis MG, Ali S, Leikauf GD, Dorn GW II. Tyrosine kinase inhibition prevents deformation-

stimulated vascular smooth muscle growth. Hypertension 24:706-713, 1994.

27. D'Angelo DD, Davis MG, Ali S, Dorn GW II. Cloning and pharmacologic characterization of a

thromboxane A2 receptor from K562 (human chronic myelogenous leukemia) cells. J Pharmacol

Exp Ther 271:1034-1041, 1994.

28. Bowling N, Dube GP, Kurtz WL, Brune KA, Saussy DL Jr, Dorn GW II, Mais DE.

Characterization of thromboxane A2/prostaglandin H2 binding sites in guinea pig cardiac

membrane preparations. J Mol Cell Cardiol 26:915-923, 1994.

29. Ali S, Becker MW, Davis MG, Dorn GW II. Dissociation of vasoconstrictor-stimulated basic

fibroblast growth factor expression from hypertrophic growth in cultured vascular smooth muscle

cells: Relevant roles of protein kinase C. Circ Res 75:836-843, 1994.

30. Ali S, Dorn GW II. Patterns of tyrosine phosphorylation differ in vascular hypertrophy and

hyperplasia. Am J Physiol 267:C1674-C1681, 1994.

31. D'Angelo DD, Davis MG, Houser WA, Eubank JJ, Ritchie ME, Dorn GW II. Characterization of

5 end of human thromboxane receptor gene: Organizational analysis and mapping of protein

kinase C-responsive elements regulating expression in platelets. Circ Res 77(3):466-474, 1995.

32. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn GW II, Lightfoot P, German R,

Howles PN, Kier A, O'Toole BA, Sasse J, Gonzalez AM, Baird A, Doetschman TC. Abnormal

bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2)

transgenic mice. Mol Biol Cell 6:1861-1873, 1995.

33. Lenihan DJ, Gerson MC, Dorn GW II, Hoit BD, Walsh RA. Effects of changes in

atrioventricular gradient and contractility on left ventricular filling in human diastolic cardiac

dysfunction. Am Heart J 132:1179-1188, 1996.

34. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW II, Walsh RA, Kranias EG.

Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant

cardiomyocyte mechanics in transgenic mice. J Clin Invest 97(2):533-539, 1996.


14


35. Gunteski-Hamblin AM, Song G, Walsh RA, Frenzke M, Boivin GP, Dorn GW II, Kaetzel MA,

Horseman ND, Dedman JR. Annexin VI overexpression targeted to heart alters cardiomyocyte

function in transgenic mice. Am J Physiol 270:H1091-H1100, 1996.

36. D'Angelo DD, Eubank JJ, Davis MG, Dorn GW II. Mutagenic analysis of platelet thromboxane

receptor cysteines: Roles in ligand binding and receptor-effector coupling. J Biol Chem

271(11):6233-6240, 1996.

37. D'Angelo DD, Oliver BG, Davis MG, McCluskey TS, Dorn GW II. Novel role for Sp1 in

phorbol ester enhancement of human platelet thromboxane receptor gene expression. J Biol Chem

271(33):19696-19704, 1996.

38. D'Angelo DD, Terasawa T, Carlisle SJ, Dorn GW II, Lynch KR. Characterization of a rat kidney

thromboxane A2 receptor: High affinity for the agonist ligand I-BOP. Prostaglandins 52:303-316,

1996.

39. Collins JF, Pawloski-Dahm C, Davis MG, Ball N, Dorn GW II, Walsh RA. The role of the

cytoskeleton in left ventricular pressure overload hypertrophy and failure. J Mol Cell Cardiol

28:1435-1443, 1996.

40. Qian J, Hendrix M, Larsen WJ, Dorn GW II, Lessard JL. Establishment and characterization of a

conditionally immortalized smooth muscle/myometrial-like cell line. Mol Reprod Dev 47:284-

294, 1997.

41. Paul K, Ball NA, Dorn GW II, Walsh RA. Left ventricular stretch stimulates angiotensin II--

mediated phosphatidylinositol hydrolysis and protein kinase C ε isoform translocation in adult

guinea pig hearts. Circ Res 81:643-650, 1997.

42. Oral H, Dorn GW II, Mann DL. Sphingosine mediates the immediate negative inotropic effects

of tumor necrosis factor- in the adult mammalian cardiac myocyte. J Biol Chem 272(8):4836-

4842, 1997.

43. Dorn GW II, Davis MG, D’Angelo DD. Structural determinants for agonist binding affinity to

thromboxane/prostaglandin endoperoxide (TP) receptors: Analysis of chimeric rat/human TP

receptors. J Biol Chem 272(19):12399-12405, 1997.

44. Dorn GW II, Oswald KJ, McCluskey TS, Kuhel DG, Liggett SB. 2A-adrenergic receptor

stimulated calcium release is transduced by Gi-associated G-mediated activation of

phospholipase C. Biochemistry 36(21):6415-6423, 1997.

44. Davis MG, Zhou M, Ali S, Coffin JD, Doetschman T, Dorn GW II. Intracrine and autocrine

effects of basic fibroblast growth factor in vascular smooth muscle cells. J Mol Cell

Cardiol 29(4):1061-1072, 1997.

45. D’Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW II.

Transgenic Gq-overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci

USA 94:8121-8126, 1997.

46. Chu G, Dorn GW II, Luo W, Harrer JM, Kadambi VJ, Walsh RA, Kranias EG. Monomeric

phospholamban overexpression in transgenic mouse hearts. Circ Res 81:485-492, 1997.

47. Sato Y, Ferguson DG, Sako H, Dorn GW II, Kadambi VJ, Yatani A, Hoit BD, Walsh RA,

Kranias EG. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with

depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem 273:28470-

28477, 1998.


15


48. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW II. Decompensation of pressure-overload

hypertrophy in Gq-overexpressing mice. Circulation 97:1488-1495, 1998.

49. Pawloski-Dahm CM, Song G, Kirkpatrick DL, Palermo J, Gulick J, Dorn GW II, Robbins J,

Walsh RA. Effects of total replacement of atrial myosin light chain-2 with the ventricular isoform

in atrial myocytes of transgenic mice. Circulation 97:1508-1513, 1998.

50. Liang M, Eason MG, Jewell-Motz EA, Williams MA, Theiss CT, Dorn GW II, Liggett SB.

Phosphorylation and functional desensitization of the 2A-adrenergic receptor by protein kinase C.

Mol Pharmacol 54:44-49, 1998.

51. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH,

Dorn GW II. Enhanced Gq Signaling: A common pathway mediates cardiac hypertrophy and

apoptotic heart failure. Proc Natl Acad Sci USA 95:10140-10145, 1998.

52. Yatani A, Frank K, Sako H, Kranias EG, Dorn GW II. Cardiac-specific overexpression of Gq

alters excitation-contraction coupling in isolated cardiac myocytes. J Mol Cell Cardiol 31:1327-

1336, 1999.

53. Tepe NM, Lorenz JN, Yatani A, Dash R, Kranias EG, Dorn GW II, Liggett SB. Altering the

receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: Enhanced basal

catalytic activity and function without increased cardiomyocyte -adrenergic signalling.

Biochemistry 38:16706-16713, 1999.

54. Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, Dorn GW II, Liggett SB. Cardiac

specific overexpression of transglutaminase II (Gh) results in a unique hypertrophy phenotype

independent of phospholipase C activation. J Biol Chem 274:21291-21296, 1999.

55. Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW II, Ross J Jr, Chien KR, Brown JH.

Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction

and contractile failure. J Clin Invest 103(12):1627-1634, 1999.

56. Dorn GW II, Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G,

Lorenz JN, Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed

peptide that causes protein kinase C translocation. Proc Natl Acad Sci USA 96:12798-12803,

1999.

57. Dorn GW II, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low- and high-level transgenic

expression of 2-adrenergic receptors differentially affect cardiac hypertrophy and function in

Gq-overexpressing mice. Proc Natl Acad Sci USA 96:6400-6405, 1999.

58. Wu G, Toyokawa T, Hahn H, Dorn GW II. Protein Kinase C in Pathological Myocardial

Hypertrophy: Analysis by combined transgenic expression of translocation modifiers and Gq.

J Biol Chem 275:29927-29930, 2000.

59. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, Abraham WT, Chenier TC,

Dorn GW II, Liggett SB. Polymorphisms of the 2-adrenergic receptor determine exercise

capacity in patients with heart failure. Circ Res 86:834-840, 2000.

60. Mochly-Rosen D, Wu G, Hahn H, Osinska H, Liron T, Lorenz JN, Yatani A, Robbins J,

Dorn GW II. Cardiotrophic effects of protein kinase C: Analysis by in vivo modulation of

PKC translocation. Circ Res 86:1173-1179, 2000.

61. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW II.

Early and delayed consequences of 2-adrenergic receptor overexpression in mouse hearts:

Critical role for expression level. Circulation 101:1707-1714, 2000.


16


62. Dorn GW II, Tepe NM, Wu G, Yatani A, Liggett SB. Mechanisms of impaired -adrenergic

receptor signaling in Gq-mediated cardiac hypertrophy and ventricular dysfunction. Mol

Pharmacol 57:278-287, 2000.

63. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW II, Kitsis RN,

Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro

and in vivo: An apoptosis-independent model of dilated heart failure. Circ Res 86:255-263, 2000.

64. Wang X, Osinska H, Dorn GW II, Nieman M, Lorenz JN, Gerdes AM, Witt S, Kimball T, Gulick

J, Robbins J. Mouse model of desmin-related cardiomyopathy. Circulation 103:2402-2407, 2001.

65. Sato Y, Kiriazis H, Yatani A, Schmidt AG, Hahn H, Ferguson DG, Sako H, Mitarai S, Honda R,

Mesnard-Rouiller L, Frank KF, Beyermann B, Wu G, Fujimori K, Dorn GW II, Kranias EG.

Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing

myocardium by phospholamban ablation. J Biol Chem 276:9392-9399, 2001.

66. Rogers JH, Tsirka A, Kovacs A, Blumer KJ, Dorn GW II, Muslin AJ. RGS4 reduces contractile

dysfunction and hypertrophic gene induction in Gq overexpressing mice. J Mol Cell Cardiol

33:209-218, 2001.

67. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn

GW II, MacLennan DH, and Kranias EG. Superinhibition of sarcoplasmic reticulum function by

phospholamban induces cardiac contractile failure. J Biol Chem 276:24145-24152, 2001.

68. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM,

Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW II, Kranias EG. Interactions between

phospholamban and β-adrenergic drive may lead to cardiomyopathy and early mortality.

Circulation 103:889-896, 2001.

69. Aronow BJ, Toyokawa T, Canning A, Haghighi K, Delling U, Kranias E, Molkentin JD, Dorn

GW II. Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy.

Physiol Genomics 6:19-28, 2001.

70. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R,

Dorn GW II, Mochly-Rosen, D. Opposing cardioprotective actions and parallel hypertrophic

effects of PKC and PKC. Proc Natl Acad Sci USA 98:11114-11119, 2001.

71. Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, Hillard GM, Wang X, Toyokawa T,

Yatani A, Lynch RA, Robbins J, Dorn GW II. Increased myocardial Rab GTPase expression: A

consequence and cause of cardiomyopathy. Circ Res. 89:1130-1137, 2001.

72. Yussman M, Toyokawa T, Odley A, Lynch R, Wu G, Colbert M, Aronow B, Dorn GW II.

Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic

cardiomyopathy. Nat Med. 8:725-730, 2002.

73. Lynch R, Wagoner L, Li S, Sparks L, Molkentin J, Dorn GW II. Novel and nondetected human

signaling protein polymorphisms. Physiol Genomics. 10:159-168, 2002.

74. Wagoner LE, Craft LL, Zengel P, McGuire N, Rath Z, Dorn GW II, Liggett SB. Polymorphisms

of the β1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J. 144:840-846,

2002.


17


75. Hahn, H, Yussman M, Toyokawa T, Marreez Y, Barrett TJ, Hilty KC, Osinska H, Robbins J,

Dorn GW II. Ischemic protection and myofibrillar cardiomyopathy: Dose-dependent effects of in

vivo δPKC inhibition. Circ Res. 91:741-748, 2002.

76. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD,

McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW II, Kranias, EG. Rescue of

cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in

genetic hypertrophy. J Clin Invest. 111:859-867, 2003.

77. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D,

Hahn HS, Adamopoulos S, Liggett SB, Dorn GW II, MacLennan DH, Kremastinos DT, Kranias

EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical

difference between mouse and human. J Clin Invest. 111:869-876, 2003.

78. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW II, Tallina G, Kroll TG,

Nikiforov YE. RAS point mutations and pax8-pparγ rearrangement in thyroid tumors: Evidence

for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinology

Metabolism. 88:2318-2326, 2003.

79. Schmidt AG, Haghighi K, Frank B, Pater L, Dorn GW II, Walsh RA, and Kranias EG.

Polymorphic SERCA2a variants do not account for inter-individual differences in

phospholamban-SERCA2a interactions in human heart failure. J Mol Cell Cardiol. 35:867-70,

2003.

80. Inagaki K, Hahn HS, Dorn GW II, Mochly-Rosen D. Additive protection of the ischemic heart

ex vivo by combined treatment with protein kinase C inhibitor and protein kinase C activator.

Circulation. 108:869-75. 2003

81. Mialet PJ, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW II,

Liggett SB. 1-adrenergic receptor polymorphisms confer differential function and predisposition

to heart failure. Nat Med. 9:1300-5, 2003

82. Howes AL, Arthur JF, Zhang T, Miyamoto S, Adams JW, Dorn GW II, Woodcock EA, Heller

Brown J. Akt-mediated cardiomyocyte survival pathways are compromised by Gq-induced

phosphoinositide 4,5-bisphosphate depletion. J Biol Chem. 278:40343-40351, 2003.

83. Hahn HS, Marreez Y, Odley A, Sterbling A, Yussman MG, Hilty C, Bodi I, Liggett SB, Schwartz

A, Dorn GW II. Protein kinase C alpha negatively regulates systolic and diastolic function in

pathologic hypertrophy. Circ Res. 93:1111-1119, 2003.

84. Hayakawa Y, Chandra M, Miao W, Shirani J, Heller Brown J, Dorn GW II, Armstrong RC,

Kitsis RN. Inhibition of cardiac myocyte apoptosis improves cardiac function and suppresses

mortality in the peripartum cardiomyopathy of Gq transgenic mice. Circulation, 108:3036-3041,

2003.

85. Gregory KN, Hahn H, Haghighi K, Marreez Y, Odley A, Dorn GW II, Kranias EG. Increased

particulate partitioning of PKC reverses susceptibility of phospholamban knockout hearts to

ischemic injury. J Mol Cell Cardiol, 36:313-318, 2004.

86. Odley A, Hahn HS, Lynch RA, Marreez Y, Osinska H, Robbins J, Dorn GW II. Regulation of

cardiac contractility by Rab 4-modulated 2-adrenergic receptor recycling. Proc Natl Acad Sci,

USA , 101:7082-7087, 2004.

87. Syed FM, Odley A, Hahn HS, Brunskill EW, Lynch RA, Marreez Y, Sanbe A, Robbins J, Dorn

GW II. Physiological growth synergizes with pathological genes in experimental cardiomyopathy.

Circ. Res., 95: 1200 - 1206, 2004.


18


88. Syed FM, Hahn HS, Odley A, Guo Y, Vallejo J, Lynch RA, Mann DL, Bolli R, Dorn GW II.

Proapoptotic effects of caspase-1/ICE dominate in myocardial ischemia. Circ. Res. 96:1103-9,

2005.

89. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen

MR, Gottlieb RA, Dorn GW II, Robbins J, and Molkentin JD. Loss of cyclophilin D reveals a

critical role for mitochondrial permeability transition in cell death. Nature. 434:658-62, 2005.

90. Miyamoto S, Howes AL, Adams JW, Dorn GW II, Heller Brown J. Ca2+ dysregulation induces

mitochondrial depolarization and apoptosis: Role of Na+/Ca2+ exchanger and Akt. J Biol Chem.

280:38505-12, 2005.

91. Brunskill EW, Ehrman LA, Williams MT, Klanke J, Hammer D, Schaefer TL, Sah R, Dorn GW

II, Potter SS and Vorhees CV. Abnormal neurodevelopment, neurosignaling and behavior in

Npas3-deficient mice. Europ J Neuroscience, 22:1265-76, 2005.

92. Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, Dorn GW II, Klevitsky R, Seidman

CE, Seidman JG and Robbins J. Cardiac myosin binding protein-C phosphorylation and cardiac

function. Circ Res. 97:1156-63, 2005

93. Galvez AS, Brunskill EW, Marreez Y, Benner BJ, Regula KM, Kirshenbaum LA, and Dorn GW

II. Distinct pathways regulate proapoptotic Nix and BNip3 in cardiac stress. J Biol Chem.

281:1442-48, 2006.

94. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D,

Parekh RR, Dorn GW II, Maclennan DH, Kremastinos DT, Kranias EG. A mutation in the

human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

Proc Natl Acad Sci U S A. 103:1388-93, 2006.

95. Zhao W, Yuan Q, Qian J, Waggoner JR, Pathak A, Chu G, Mitton B, Sun X, Jin J, Braz JC, Hahn

HS, Marreez Y, Syed F, Pollesello P, Annila A, Wang HS, Schultz Jel J, Molkentin JD, Liggett

SB, Dorn GW II, Kranias EG. The presence of Lys27 instead of Asn27 in human

phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac

remodeling. Circulation. 113:995-1004, 2006.

96. Gregory KN, Ginsburg KS, Bodi I, Hahn H, Marreez YM, Song Q, Padmanabhan PA, Mitton BA,

Waggoner JR, Del Monte F, Park WJ, Dorn GW II, Bers DM, Kranias EG. Histidine-rich Ca

binding protein: a regulator of sarcoplasmic reticulum calcium sequestration and cardiac function.

J Mol Cell Cardiol. 40:653-665, 2006.

97. Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, Kimball TF, Hewett TE,

Dorn GW II, Koch WJ, Molkentin JD. Pharmacological- and gene therapy-based inhibition of

protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure.

Circulation.114:574-82, 2006.

98. Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley A, Brunskill EW, Koch WJ,

Schwartz RJ, Dorn GW II. Cardiac-specific ablation of GRK2 re-defines its roles in heart

development and -adrenergic signaling. Circ Res, 99:996-1003, 2006.

99. Yuan Q, Fan GC, Dong M, Altschafl B, Diwan A, Ren X, Hahn HH, Zhao W, Waggoner JR,

Jones LR, Jones WK, Bers DM, Dorn GW II, Wang HS, Valdivia HH, Chu G, Kranias EG.

Sarcoplasmic reticulum calcium overloading in junctin deficiency enhances cardiac contractility

but increases ventricular automaticity. Circulation. 115:300-9, 2007.


19


100. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG, Robbins J, Lynch RA,

Marreez Y and Dorn GW II. Cardiomyocyte degeneration with cardiac calpain deficiency

reveals a critical role in protein homeostasis. Circ Res. 100:1071-8, 2007.

101. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang M-L, Segnalini P, Gu Y,

Dalton ND, Latronico MVP, Høydal M, Autore C, Russo MA, Dorn GW II, Ellingsen Ø, Ruiz-

Lozano P, Peterson KL, Croce CM, Peschle C, and Condorelli G. MicroRNA-133 controls

cardiac hypertrophy. Nat Med. 13:613-8, 2007.

102. Diwan A, Koesters AG, Odley AM, Pushkaran S, Baines CP, Spike BT, Daria D, Jegga AG,

Geiger H, Aronow BJ, Molkentin JD, Macleod KF, Kalfa TA, and Dorn GW II. Unrestrained

erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of

erythropoiesis. Proc Natl Acad Sci, USA. 104:6794-9, 2007.

103. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW, Dorn

GW II, Conway SJ, Aronow BJ, Robbins J, Molkentin JD. Genetic manipulation of periostin

expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res. 101:313-

21, 2007.

104. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn GW II, Liao JK. Inhibition of

apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen.

Circulation. 115:3197-204, 2007.

105. Nakamura T, Colbert M, Krenz M, Molkentin JD, Hahn HS, Dorn GW II and Robbins J.

Mediating ERK1/2 signaling rescues congenital heart defects in a mouse model of Noonan

syndrome. J Clin Invest. 117:2123-32, 2007.

106. Liggett SB, Kelly RJ, Parekh RR, Benner BJ, Hahn HS, Matkovich SJ, Syed FM, Galvez AS,

Case KL, McGuire N, Odley AM, Sparks Li, Kardia SLR, and Dorn GW II. A functional

polymorphism of the Gq (GNAQ) gene is associated with accelerated mortality in African

American heart failure. Hum Mol Genet, 16:2740-50, 2007.

107. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn

HS, Robbins J, Jones WK, and Dorn GW II. Inhibition of ischemic cardiomyocyte apoptosis

through targeted ablation of Bnip3 restrains post-infarction remodeling. J Clin Invest, 117: 2825-

2833, 2007.

108. Shi J, Zhang YW, Summers LJ, Dorn GW II, and Wei L. Disruption of ROCK1 gene attenuates

cardiac dilation and improves contractile function in pathological cardiac hypertrophy. J Mol Cell

Cardiol. 44:551-60, 2008.

109. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN and Dorn GW II. Nix-mediated

apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation.

Circulation, 117:396-404, 2008.

110. Haghighi K, Chen G, Sato Y, Fan G-C, He S, Kolokathis F, Pater L, Paraskevaidis I, Jones WK,

Dorn GW II, Kremastinos DT, and Kranias EG. A human phospholamban promoter

polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids.

Hum Mutat. 29:640-7, 2008.

111. Chen G, Zhou X, Nicolaou P, Rodriguez P, Song G, Mitton B, Pathak A, Zachariah A, Fan GC,

Dorn GW II, and Kranias EG. A human polymorphism of protein phosphatase-1 inhibitor-1 is

associated with attenuated contractile response of cardiomyocytes to -adrenergic stimulation.

FASEB J, 22:1790-6, 2008.


20


112. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks

L, Parekh RR, Spertus JA, Koch WJ, Kardia SLR, and Dorn GW II. A GRK-5 polymorphism

that inhibits -adrenergic receptor signaling is protective in heart failure. Nat Med, 14:510-7,

2008.

113. Ozgen N, Obreztchikova M, Guo J, Elouardighi H, Dorn GW II, Wilson BA, and Steinberg SF.

Protein kinase D links Galpha q-coupled receptors to CREB-S133 phosphorylation in the heart.

J Biol Chem. 283:17009-19, 2008.

114. Pott C, Willkomm L, Grafweg S, Bölck B, Dorn GW II, Schwinger RH, and Brixius K. Reduced

troponin I phosphorylation and increased Ca(2+)-dependent ATP-consumption in triton X-skinned

fiber preparations from Galphaq overexpressor mice. Mol Cell Biochem. 314:133-41, 2008.

115. Diwan A, Koesters AG, Capella D, Geiger H, Kalfa TA, and Dorn GW II. Targeting erythroblast-

specific apoptosis in experimental anemia. Apoptosis. 13:1022-30, 2008.

116. Arvanitis DA, Sanoudou D, Kolokathis F, Vafiadaki E, Papalouka V, Kontrogianni-

Konstantopoulos A, Theodorakis GN, Paraskevaidis IA, Adamopoulos S, Dorn GW II,

Kremastinos DT, and Kranias EG. The Ser96Ala variant in histidine-rich calcium-binding protein

is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy.

Eur Heart J, 29:2514-25, 2008.

117. Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, Degeorge BR Jr, Matkovich S,

Houser SR, Most P, Eckhart AD, Dorn GW II, and Koch WJ. G protein-coupled receptor kinase

2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ

Res. 103:413-22, 2008.

118. Cohn HI, Harris DM, Pesant S, Pfeiffer M, Zhou RH, Koch WJ, Dorn GW II, Eckhart AD.

Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances 1DAR

constriction. Am J Physiol Heart Circ Physiol. 295:H1695-704, 2008.

119. Nicolaou P, Knöll R, Haghighi K, Fan GC, Dorn GW II, Hasenfuß G, Kranias EG. A human

mutation in the anti-apoptotic heat shock protein 20 abrogates its cardioprotective effects. J Biol

Chem. 283:33465-33471, 2008.

120. Kardia SL, Kelly RJ, Keddache MA, Aronow BJ, Grabowski GA, Hahn HS, Case KL, Wagoner

LE, Dorn GW II, Liggett SB. Multiple interactions between the alpha2C- and beta1-adrenergic

receptors influence heart failure survival. BMC Med Genet. 9:93, 2008.

121. Sheikh F, Raskin A, Chu PH, Lange S, Domenighetti AA, Zheng M, Liang X, Zhang T, Yajima T,

Gu Y, Dalton ND, Mahata SK, Dorn GW II, Heller-Brown J, Peterson KL, Omens JH,

McCulloch AD, Chen J. An FHL1-containing complex within the cardiomyocyte sarcomere

mediates hypertrophic biomechanical stress responses in mice. J Clin Invest. 118:3870-8, 2008.

122. Petrashevskaya N, Gaume BR, Mihlbachler KA, Dorn GW II, Liggett SB. Bitransgenesis with

2-adrenergic receptors or adenylyl cyclase fails to improve -adrenergic receptor

cardiomyopathy. Clin Transl Sci. 1:221-227, 2008.

123. Chen G, Zhou X, Pathak A, Dorn GW II, Kranias EG. The human G147D-protein phosphatase 1

inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure.

Cardiology. 112:224-231, 2009.

124. Diwan A, Matkovich SJ, Yuan Q, Zhao W, Yatani A, Heller-Brown J, Molkentin JD, Kranias EG,

Dorn GW II. Endoplasmic reticulum-mitochondrial crosstalk in Nix-mediated murine cell death.

J Clin Invest. 119:203-212, 2009.


21


125. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn

LE, Watson MA, Margulies KB, Dorn GW II. Reciprocal regulation of myocardial miR and

mRNA in human cardiomyopathy and reversal of the miR signature by biomechanical support.

Circulation, 119:1263-71, 2009.

126. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SLR, Dorn GW II. Clinical and

genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol, 54:432-44, 2009.

127. Sosnovik DE, Nahrendorf M, Panizzi P, Matsui T, Aikawa E, Dai G, Li L, Reynolds F, Dorn GW

II, Weissleder R, Josephson L, Rosenzweig A. Molecular MRI detects low levels of

cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ Cardiovasc Imaging

2:468-75, 2009

128. Matkovich SJ, van Booven DJ, Hindes A, Kang MY, Druley TE, Vallania FLM, Mitra RB, Reilly

MP, Cappola TP, Dorn GW II. Cardiac signaling genes exhibit unexpected sequence diversity in

sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. J Clin Invest,

120:280-9, 2010.

129. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne

JM, Dorn GW II. MicroRNA-133a protects against myocardial fibrosis and modulates electrical

repolarization without affecting hypertrophy in pressure overloaded adult hearts. Circ Res,

106:166-75, 2010.

130. Nijboer CH, Heijnen CJ, Willemen HL, Groenendaal F, Dorn GW II, Bel FV, Kavelaars A. Cell-

specific roles of GRK2 in onset and severity of hypoxic-ischemic brain damage in neonatal mice.

Brain Behav Immun, 24:420-6, 2010.

131. Cappola TP, Li M, He J, Ky B, Gilmore J, Qu L, Keating B, Reilly M, Kim CE, Glessner J,

Frackelton E, Hakonarson H, Syed F, Hindes A, Matkovich SJ, Cresci S, Dorn GW II. Common

variants in HSPB7 and FRMD4B associated with advanced heart failure. Circ Cardiovasc Genet,

3:147-54, 2010.

132. Qin F, Lennon-Edwards S, Lancel S, Biolo A, Siwik DA, Pimentel DR, Dorn GW II, Kang YJ,

Colucci WS. Cardiac-specific Overexpression of Catalase Identifies Hydrogen Peroxide-

dependent and Independent-phases of Myocardial Remodeling, and Prevents the Progression to

Overt Heart Failure in Gq-overexpressing Transgenic Mice. Circ Heart Fail, 3:306-13, 2010.

133. Eijkelkamp N, Heijnen CJ, Willemen HL, Deumens R, Joosten EA, Kleibeuker W, den Hartog IJ,

van Velthoven CT, Nijboer C, Nassar MA, Dorn GW II, Wood JN, Kavelaars A. GRK2: A Novel

Cell-Specific Regulator of Severity and Duration of Inflammatory Pain. J Neuroscience, 30:2138-

49, 2010.

134. Dorn GW II. Mitochondrial Pruning by Nix and BNip3: An essential function for cardiac-

expressed death factors. J Cardiovasc Transl Res, 3:374-83, 2010.

135. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW II, Koch WJ. Reduction of sympathetic

activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and

improves cardiac function after myocardial infarction. J Biol Chem, 285:16378-86, 2010.

136. Matkovich SJ, Zhang Y, van Booven D, Dorn GW II. Deep mRNA sequencing for in vivo

functional analysis of cardiac transcriptional regulators: Application to Gq. Circ Res, 106:1459-

67, 2010.


22


137. Chen Y, Lewis W, Diwan A, Cheng E H-Y, Matkovich SJ, Dorn GW II. Dual autonomous

mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. Proc

Natl Acad Sci USA (Feature Article) 107:9035-42, 2010.

138. Fujimoto K, Chen Y, Polonsky KS, Dorn GW II. Targeting cyclophilin D and the mitochondrial

permeability transition enhances -cell survival and prevents diabetes in Pdx1 deficiency. Proc

Natl Acad Sci USA, 107:10214-9, 2010.

139. Matkovich SJ, Van Booven DJ, Cappola TP, Dorn GW II. Association of an intronic, but not any

exonic, FRMD4B sequence variant and heart failure. Clin Transl Sci 3:134-9, 2010.

140. Ding W-Y, Ni H-M, Li M, Liao Y, Chen X, Stolz DB, Dorn GW II, Tin X-M. Nix is critical to

two distinct phases of mitophagy: Reactive Oxygen Species (ROS)-mediated autophagy induction

and Parkin-ubiquitin-p62-mediated mitochondria pruning. J Biol Chem 285:27879-90, 2010.

141. Willemen HL, Eijkelkamp N, Wang H, Dantzer R, Dorn GW II, Kelley KW, Heijnen CJ,

Kavelaars A. Microglial GRK2 determines duration of peripheral IL-1-induced hyperalgesia:

Contribution of spinal cord CX3CR1, p38 and IL-1 signaling. Pain 150:550-60, 2010.

142. Cresci S, Huss JM, Beitelshees AL, Jones PG, Minton MR, Dorn GW II, Kelly DP, Spertus JA,

McLeod HL. A PPARa promoter variant impairs ERR-dependent transactivation and decreases

mortality after acute coronary ischemia in patients with diabetes. PLoS ONE 5:e12584, 2010.

143. Kang MY, Zhang Y, Matkovich SJ, Diwan A, Chishti AH, and Dorn GW II. Receptor-

Independent Cardiac Protein Kinase C Activation by Calpain-Mediated Truncation of

Regulatory Domains. Circ Res 107:903-12, 2010.

144. Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer

N, Bhattacharya J, Bogaard H, Choudhary G, Dorn GW II, Dweik R, Fagan K, Fallon M, Finkel

T, Geraci M, Gladwin MT, Hassoun PM, Humbert M, Kaminski N, Kawut SK, Loscalzo J,

McDonald D, McMurtry IF, Newman J, Nicolls M, Rabinovitch M, Shizuru J, Oka M, Polgar P,

Rodman D, Schumacker P, Stenmark K, Tuder R, Voelkel N, Sullivan E, Weinshilboum R, Yoder

MC, Zhao Y, Gail D, Moore TM. Strategic Plan for Lung Vascular Research: An NHLBI-ORDR

Workshop Report. Am J Respir Crit Care Med, 182:1554-62, 2010.

145. Fujimoto K, Ford EL, Tran H, Wice BM, Crosby SD, Dorn GW II, Polonsky KS. Interrupting

Nix upregulation in Pdx1 deficiency prevents apoptotic and necrotic beta-cell death, and murine

diabetes. J Clin Invest, 120:4031-9, 2010.

146. Patial S, Saini Y, Parvataneni S, Appledorn DM, Dorn GW II, Lapres JJ, Amalfitano A, Senagore

P, Parameswaran N. Myeloid-specific GPCR kinase-2 negatively regulates NFkappaB1p105-

ERK pathway and limits endotoxemic shock in mice. J Cell Physiol, 226:627-37 2011.

147. Lanktree MB, Guo Y, Murtaza M, et al. Meta-analysis of dense genecentric association studies

reveals common and uncommon variants associated with height. Am J Hum Genet. 88:6-18, 2011.

148. Matkovich SJ, van Booven DJ, Eschenbacher WH, Dorn GW II. RISC RNA sequencing for

context-specific identification of in vivo miR targets. Circ Res, 108:18-26, 2011.

149. Dorn GW II, Clark CF, Eschenbacher WH, Kang M-Y, Engelhard JT, Warner SJ, Matkovich SJ,

Jowdy CC. MARF and Opa1 control mitochondrial and cardiac function in Drosophila. Circ Res,

108:12-17, 2011.

150. Cappola TP, Matkovich SJ, Wang Wei, Van Booven DJ, Li M, Wang X, Qu L, Sweitzer NK, Fang

JC, Reilly M, Hakonarson H, Nerbonne JM, Dorn GW II. Loss-of-function DNA sequence

variant in the CLCNKA chloride channel implicates the cardio-renal axis in inter-individual heart

failure risk variation. Proc Natl Acad Sci USA, 108:2456-61, 2011.


23


151. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintrón M, Chen T, Marcinek DJ, Dorn GW

II, Kang YJ, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial Oxidative Stress Mediates

Angiotensin II-Induced Cardiac Hypertrophy and Gq Overexpression-Induced Heart Failure.

Circ Res, 108:837-46, 2011.

152. Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ, Gold J, Gumpert A, Chen M,

Otis NJ, Dorn GW II, Trimarco B, Iaccarino G, Koch WJ. GRK2 activity impairs cardiac

glucose uptake and promotes insulin resistance following myocardial ischemia. Circulation,

123:1953-62, 2011.

153. Rodriguez G, Ueyama T, Ogata T, Czernuszewicz G, Tan Y, Dorn GW II, Bogaev R, Amano K,

Oh H, Matsubara H, Willerson JT, Marian AJ. Molecular Genetic and Functional Characterization

Implicate Muscle-Restricted Coiled-Coil Gene (MURC) as a Causal Gene for Familial Dilated

Cardiomyopathy. Circ Cardiovasc Genet, 4:349-58, 2011.

154. Zhang Y, Matkovich SJ, Duan W, Gold JI, Koch WJ, Dorn GW II. Nuclear effects of GRK5 on

HDAC5-regulated gene transcription in heart failure. Circ Heart Fail, 4:659-68, 2011.

155. Xiang SY, Vanhoutte D, Del Re DP, Purcell NH, Ling H, Banerjee I, Bossuyt J, Lang RA, Zheng

Y, Matkovich SJ, Miyamoto S, Molkentin JD, Dorn GW II, Brown JH. RhoA protects against

ischemia/reperfusion injury. J Clin Invest, 121:3269-76, 2011.

156. Zhang Y, Matkovich SJ, Diwan A, Kang M-Y, Dorn GW II. Receptor-independent PKC

signaling by calpain-generated free catalytic domains induces HDAC5 nuclear export and

regulates cardiac transcription. J Biol Chem, 286:26943-51, 2011.

157. Lin CH, Kurup S, Herrero P, Schechtman KB, Eagon JC, Klein S, Dávila-Román VG, Stein RI,

Dorn GW II, Gropler RJ, Waggoner AD, Peterson LR. Myocardial oxygen consumption change

predicts left ventricular relaxation improvement in obese humans after weight loss. Obesity

19:1804-12, 2011.

158. Razani B, Zhang H, Schulze PC, Schilling JD, Verbsky J, Lodhi IJ, Topkara VK, Feng C,

Coleman T, Kovacs A, Kelly DP, Saffitz JE, Dorn GW II, Nichols CG, Semenkovich CF. Fatty

acid synthase modulates homeostatic responses to myocardial stress. J Biol Chem, 286:30949-61,

2011.

159. Porrello ER, Johnson BA, Aurora AB, Simpson E, Nam YJ, Matkovich SJ, Dorn GW II, van

Rooij E, Olson EN. miR-15 family regulates postnatal mitotic arrest of cardiomyocytes.

Circ Res, 109:670-9, 2011.

160. Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, Dorn GW II, and Cyster JG. GRK2-

dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction for

blood. Science, 333:1891-1903, 2011.

161. Chen Y, Liu Y, Dorn GW II. Mitochondrial fusion is essential for organelle function and cardiac

homeostasis. Circ Res, 109:1327-31, 2011.

162. Fusco A, Santulli G, Sorriento D, Cipolletta E, Garbi C, Dorn GW II, Trimarco B, Feliciello A,

Iaccarino G. Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis.

Cell Signal, 24:468-75, 2012.

163. Zhu W, Petrashevskaya N, Ren S, Zhao A, Chakir K, Gao E, Chuprun JK, Wang Y, Talan M,

Dorn GW II, Lakatta EG, Koch WJ, Feldman AM, Xiao R-P. Gi-biased 2AR signaling links

GRK2 upregulation to heart failure. Circ Res, 110:265-74, 2012.

164. Saxena R, Elbers CC, Guo Y, et al. Large-scale gene-centric meta-analysis across 39 studies

identifies type 2 diabetes loci. Am J Hum Genet, 90:410-25, 2012.


24


165. Dorn GW II, Matkovich SJ, Eschenbacher WH, Zhang Y. A human 3’ miR-499 mutation alters

cardiac mRNA targeting and function. Circ Res, 110:958-67, 2012.

166. Cresci S, Dorn GW II, Jones PG, Beitelshees AL, Li AY, Lensini PA, Province MA, Spertus JA,

Lanfear DE. Adrenergic-pathway gene variants influence -blocker-related outcomes after acute

coronary syndrome in a race-specific manner. J Am Coll Cardiol. 60:898-907, 2012.

167. Raake PW, Zhang X, Vinge LE, Brinks H, Gao E, Jaleel N, Li Y, Tang M, Most P, Dorn GW II,

Houser SR, Katus HA, Chen X, Koch WJ. Cardiac GRK2 ablation induces a novel Ca2+ handling

phenotype resistant to adverse alterations and remodeling after myocardial infarction.

Circulation, 125:2108-18, 2012.

168. Whelan R, Konstantinidis K, Wei A-C, Chen Y, Reyna DE, Jha S, Yang Y, Calvert JW, Lindsten

T, Thompson CB, Crow M, Gavathiotis E, Dorn GW II, O’Rourke B, Kitsis RN. Bax regulates

primary necrosis through mitochondrial dynamics. Proc Nat Acad Sci, USA. 109:6566-7, 2012.

169. Glick DV, Zhang W, Beaton M, Marsboom G, Gruber M, Simon MC, Hart J, Dorn GW II, Brady

MJ, Macleod K. BNip3 regulates mitochondrial function and lipid metabolism in the liver. Mol

Cell Biol, 32:2570-48, 2012.

170. Lee MJ, Kim DE, Zakrzewska A, Yoo YD, Kim S, Kim ST, Seo JW, Lee YS, Dorn GW II, Oh

UT, Kim BY, Kwon YT. Characterization of the arginylation branch of the N-End Rule Pathway

in G-protein-mediated proliferation and signaling of cardiomyocytes. J Biol Chem, 287:24043-52,

2012.

171. Tao W, Shi J, Dorn GW II, Wei L, Rubart M. Spatial variability in T-tubule and electrical

remodeling of left ventricular epicardium in mouse hearts with transgenic Gαq overexpression-

induced pathological hypertrophy. J Mol Cell Cardiol, 53:409-19, 2012.

172. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW II. Direct and indirect involvement

of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res, 111:521-31, 2012.

173. Chen Y, Csordas G, Jowdy C, Schneider TG, Wang W, Liu Y, Kohlhaas M, Meiser M, Bergem S,

Nerbonne JM, Dorn GW II*, Maack C* (* co-contributing authors). Mitofusin 2-containing

mitochondrial-reticular microdomains direct rapid cardiomyocyte bioenergetic response via inter-

organelle Ca2+ crosstalk. Circ Res, 111:863-75, 2012.

174. Eschenbacher WH, Song M, Chen Y, Zhao P, Jowdy CC, Engelhard JT, Dorn GW II. Two rare

human mitofusin 2 mutations alter mitochondrial dynamics and induce retinal and cardiac

pathology in Drosophila. PLoS One, 7:e44296, 2012.

175. Hu Y, Matkovich SJ, Hecker PA, Zhang Y, Edwards JR, Dorn GW II. Epitranscriptional

orchestration of genetic reprogramming is an emergent property of stress-regulated cardiac

microRNAs. Proc Nat Acad Sci, USA, 109:19864-9, 2012.

176. Guo Y, Lanktree MB, Taylor KC, et al. Gene-centric meta-analyses of 108 912 individuals

confirm known body mass index loci and reveal three novel signals. Hum Mol Genet, 22:148-201,

2013.

177. Cao DJ, Jiang N, Blagg A, Johnstone JL, Gondalia R, Oh M, Luo X, Yang KC, Shelton JM,

Rothermel BA, Gillette TG, Dorn GW II, Hill JA. Mechanical Unloading Activates FoxO3 to

Trigger Bnip3-Dependent Cardiomyocyte Atrophy. J Am Heart Assoc. 2:e000016, 2013.

178. Matkovich SJ, Hu Y, Dorn GW II, Regulation of cardiac microRNAs by cardiac microRNAs.

Circ Res, 113:62-71, 2013.

179. Chen Y and Dorn GW II. PINK1-phosphorylated Mitofusin 2 is a Parkin receptor for culling

damaged mitochondria. Science, 340:471-5, 2013.


25


180. Kasahara A, Cipolat S, Chen Y, Dorn GW II*, Scorrano L* (* co-contributing authors).

Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin/notch signaling.

Science, 342:734-7, 2013.

181. Chen Y, Decker KF, Zheng D, Matkovich SJ, Jia L, and Dorn GW II. A nuclear-targeted

alternately spliced Nix/Bnip3L isoform modifies NF-B mediated cardiac transcription. J Biol

Chem, 288:15455-65, 2013.

182. Vasudevan NT, Mohan ML, Gupta MK, Martelli EE, Hussain AK, Qin Y, Chandrasekharan UM,

Young D, Feldman AM, Sen S, Dorn GW II, Dicorleto PE, Naga Prasad SV. Gβγ independent

recruitment of G-protein coupled receptor kinase 2 drives TNFα-induced cardiac beta-adrenergic

receptor dysfunction. Circulation, 128:377-87, 2013.

183. Fan Q, Chen M, Zuo L, Shang X, Huang MZ, Ciccarelli M, Raake P, Brinks H, Chuprun KJ,

Dorn GW II, Koch WJ, Gao E. Myocardial ablation of G protein-coupled receptor kinase 2

(GRK2) decreases ischemia/reperfusion injury through an anti-intrinsic apoptotic pathway. PLoS

One, 8:e66234, 2013.

184. Ciccarelli M, Sorriento D, Franco A, Fusco A, Del Giudice C, Annunziatam R, Cipolletta E,

Monti MG, Dorn GW II, Trimarco B, Iaccarino G. Endothelial GRK2 regulates vascular

homeostasis through the control of free radical oxygen species. Atheroscler Thromb Vasc Biol,

33:2415-24, 2013.

185. Sorriento D, Fusco A, Ciccarelli M, Rungi A, Anastasio A, Carillo A, Dorn GW II, Trimarco B,

Iaccarino G. Mitochondrial G protein coupled receptor kinase 2 regulates proinflammatory

responses in macrophages. FEBS Lett, 587:3487-94 2013.

186. Rivas V, Carmona R, Muñoz-Chápuli R, Mendiola M, Nogués L, Reglero C, Miguel-Martín M,

García-Escudero R, Dorn GW II, Hardisson D, Mayor F Jr, Penela P. Developmental and tumoral

vascularization is regulated by G protein-coupled receptor kinase 2. J Clin Invest, 123:4714-30,

2013.

187. Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V,

Matkovich SJ, Dorn GW II, French AR, Fehniger TA. MicroRNA-155 tunes both the threshold

and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol,

191:504-13, 2013.

188. Bhandari P, Song M, Chen Y, Burelle Y, Dorn GW II. Mitochondrial contagion induced by

Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin. Circ Res

114:257-65, 2014.

189. Chen S, Puthanveetil P, Feng B, Matkovich SJ, Dorn GW II, Chakrabarti S. Cardiac miR-133a

overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med, 18:415-21, 2014.

190. Puckelwartz M, Pesce L, Nelakuditi V, Dellefave-Castillo L, Golbus J, Day S, Cappola T, Dorn

GW II, Foster I, McNally E. Supercomputing for the parallelization of whole genome analysis.

Bioinformatics, 30:1508-13, 2014.

191. Song M, Chen Y, Gong G, Murphy E, Rabinovitch P, Dorn GW II. Super-suppression of

mitochondrial ROS signaling impairs compensatory autophagy in primary mitophagic

cardiomyopathy. Circ Res, 115:348-53, 2014.

192. Matkovich SJ, Edwards JR, Grossenheider TC, de Guzman Strong C, Dorn GW II. Epigenetic

coordination of embryonic heart transcription by dynamically regulated lncRNAs. Proc Natl Acad

Sci USA, 111:12264-9, 2014.


26

193. Danielli A, Maslov K, Garcia-Uribe A, Winkler AM, Li C, Wang L, Chen Y, Dorn GW II, Wang

L. Label-free photoacoustic nanoscopy. J Biomed Opt, 19:86006, 2014.


27


194. Chen Y, Sparks M, Bhandari P, Matkovich SJ, Dorn GW II. Mitochondrial genome linearization

is a causative factor for cardiomyopathy in mice and Drosophila. Antioxid Redox Signal, 21:1949-

59, 2014.

195. Dhingra R, Margulets V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, Dorn GW II,

Kirshenbaum LA. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality

through changes in mitochondrial signaling. Proc Natl Acad Sci USA, 111:E5537-44, 2014.

196. Song M, Mihara K, Chen Y, Scorrano L, Dorn GW II. Mitochondrial fission and fusion factors

reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. Cell Metab,

21:273-85, 2015.

197. Bhandari P, Song M, Dorn GW II. Dissociation of mitochondrial from sarcoplasmic reticular

stress in Drosophila cardiomyopathy induced by molecularly distinct mitochondrial fusion

defects. J Mol Cell Cardiol, 80C:71-80, 2014.

198. Picard M, McManus M, Csordas G, Varnai P. Dorn GW II, Williams D, Hajnoczky G, Wallace

DC. Trans-mitochondrial coordination of cristae at regulated membrane junctions. Nat Commun,

6:6259, 2015.

199. Westenbrink BD, Ling H, Miyamoto S, Divakaruni A, Gray CB, Zambon AC, Dalton ND,

Peterson K, Gu Y, Matkovich SJ, Murphy AN, Dorn GW II, Heller Brown J. Mitochondrial

reprogramming induced by CaMKII mediates hypertrophy decompensation. Circ Res, 116:e28-

39, 2015.

200. Song M, Matkovich SJ, Zhang Y, Hammer DJ, and Dorn GW II. Combined cardiomyocyte

PKC and PKC gene deletion uncovers their central role in restraining developmental and

reactive heart growth. Sci Signal, 8:ra39, 2015.

201. Song M, Guong G, Burelle Y, Gustafsson AB, Kitsis RN, Matkovich SJ, and Dorn GW II.

Interdependence of Parkin-mediated mitophagy and mitochondrial fission in adult mouse hearts.

Circ Res, 117:346-51, 2015.

202. Gong G, Song M, Csordas G, Kelly DP, Matkovich SJ, and Dorn GW II. Parkin-mediated

mitophagy directs perinatal cardiac metabolic maturation in mice. Science, 350:aad2459, 2015.

203. Matkovich SJ, Dorn GW II, Grossenheider TC, Hecker PA. Cardiac disease status dictates

functional mRNA targeting profiles of individual microRNAs. Circ Cardiovasc Genet, 8:774-84,

2015.

204. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for

monitoring autophagy (3rd edition). Autophagy, 12:1-222, 2016.

205. Murphy E, Ardehali H, Balaban RS, DiLisa F, Dorn GW II, et al. Mitochondrial Function,

Biology, and Role in Disease: A Scientific Statement From the American Heart Association. Circ

Res, 118:1960-91, 2016.

206. Hall AR, Burke N, Dongworth RK, Kalkhoran SB, Dyson A, Vicencio JM, Dorn GW II, Yellon

DM, Hausenloy DJ. Hearts deficient in both Mfn1 and Mfn2 are protected against acute

myocardial infarction. Cell Death Dis. 7:e2238, 2016.

207. O’Sullivan TE, Geary CD, Weizman OE, Geiger TL, Rapp M, Dorn GW II, Overholtzer M, Sun

JC. Atg5 is essential for the development and survival of innate lymphocytes. Cell Rep, 15:1910-

19, 2016.

208. Tol MJ, Ottenhoff R, van Eijk M, Zelcer N, Aten J, Houten SM, Geerts D, van Roomen C,

Bierlaagh MC, Scheij S, Hoeksema MA, Aerts JM, Bogan JS, Dorn GW II, Argmann CA,


28

Verhoeven AJ. A PPARγ-Bnip3 axis couples adipose mitochondrial fusion-fission balance to

systemic insulin sensitivity. Diabetes, 65:2591-605, 2016.


29


209. Franco A, Kitsis RN, Fleischer JA, Gavathiotis E, Kornfeld OS, Gong G, Biris N, Benz A, Qvit N,

Donnelly SK, Chen Y, Mennerick S, Hodgson L, Mochly-Rosen D, Dorn GW II. Correcting

mitochondrial fusion by manipulating mitofusin conformations. Nature 540:74-79, 2016.

210. Naon D, Zaninelo M, Giacomello M, Varanita T, Grespi F, Lakshminaranayan S, Serafini A,

Semenzato M, Herkenne S, Hernande-Alvarez MI, Zorzano A, de Stafani D, Dorn GW II,

Scorrano L. Critical reappraisal confirms that Mitofusin 2 is an endoplasmic reticulum-

mitochondria tether. Proc Natl Acad Sci, USA. 113:11249-54, 2016.

211. Hammerling BC, Najor RH, Cortez MQ, Shires SE, Leon LJ, Gonzalez ER, Boassa D, Phan S,

Thor A, Jimenez RE, Li H, Kitsis RN, Dorn GW II, Sadoshima J, Ellisman MH, Gustafsson ÅB.

A Rab5 endosomal pathway mediates Parkin-dependent mitochondrial clearance. Nat Commun

8:14050, 2017.

212. Speir M, Vogrin A, Seidi A, Abraham G, Hunot S, Han Q, Dorn GW II, Masters SM, Flavell R,

Vice JE, Naderer T. Legionella pneumophila strain 130b evades macrophage cell death

independent of the effector SidF in the absence of flagellin. Front Cell Infect Micro, 7:35 doi:

10.3389/fcimb.2017.00035, 2017.

213. Beikoghli Kalkhoran S, Hall AR, White IJ, Cooper J, Fan Q, Ong SB, Hernández-Reséndiz S,

Cabrera-Fuentes H, Chinda K, Chakraborty B, Dorn GW II, Yellon DM, Hausenloy DJ.

Assessing the effects of mitofusin 2 deficiency in the adult heart using 3D electron tomography.

Physiol Rep. 5: e13437, 2017.

214. Song M, Franco A, Fleischer JA, Zhang L, Dorn GW II. Abrogating mitochondrial dynamics in

mouse hearts accelerates mitochondrial senescence. Cell Metabol. 26:872-885, 2017.

215. Xu H, Dorn GW II, Shetty A, Parihar A, Dave T, Robinson SW, Gottlieb SS, Donahue MP,

Tomaselli GF, Kraus WE, Mitchell BD, Liggett SG. A Genome-Wide Association Study of

Idiopathic Dilated Cardiomyopathy in African Americans. J Pers Med. 8:11 doi:10.3390/

jpm8010011, 2018.

216. Rocha AG, Franco A, Krezel AM, Runsey JM, Alberti JM, Knight WC, Biris N, Zacharioudakis

E, Janetka JW, Baloh RH, Kitsis RN, Mochly-Rosen D, Townsend RR, Gavathiotis E, Dorn GW

II. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot Marie Tooth

disease type 2A. Science, 360: 336-341, 2018.

217. Franco A, Zhang L, Matkovich SJ, Kovacs A, Dorn GW II. G-protein receptor kinases 2, 5, and

6 modulate Smoothened-GATA transcriptional crosstalk in fetal mouse hearts. J Mol Cell Cardiol,

121:60-68, 2018.

218. Von Schulze A, McCoin CS, Onyekere C, Allen JA, Geiger OC, Dorn GW II, Morris EM,

Thyfault JP. Hepatic mitochondrial adaptations to physical activity: impact of sexual dimorphism,

PGC1α, and BNIP3 mediated mitophagy. J Physiol, 596:6157-71, 2018.

219. Zhou Y, Carmona S, Muhammad AKMG, Bell S, Landeros J, Vazquez M, Ho R, Franco A, Lu B,

Dorn GW II, Wang S, Lutz CM, Baloh RH. Restoring mitofusin balance prevents axonal

degeneration in CMT2A model mice. J Clin Invest, 130:1756-71, 2019.

220. Thai PN, Seidlmayer LK, Miller C, Ferrero M, Dorn GW II, Schaefer S, Bers DM, Dedkova EN.

Mitochondrial quality control in aging and heart failure: Influence of ketone bodies and mitofusin

stabilizing-peptides. Front Physiol, 10:382. doi:10.3389/fphys.2019.00382, 2019.

221. Seidlmayer LK, Mages C, Berbner A, Eder-Negrin P, Arias-Loza P, Kaspar M, Song M, Dorn

GW II, Kohlhaas M, Frantz S, Maack C, Gerull B, Dedkova EN. Mitofusin 2 is essential for IP3-


30

mediated SR/mitochondrial metabolic feedback in ventricular myocytes. Front Physiol, 10:733.

doi:10.3389/fphys.2019.00733, 2019.

222. McCoin CS, Von Schulze A, Allen J, Fuller KNZ, Xia Q, Koestler DC, Houchen CJ, Maurer A,

Dorn GW II, Shankar K, Morris EM, Thyfault JP.Sex modulates hepatic mitochondrial

adaptations to high-fat diet and physcial activity. Am J Physiol Endocrinol Metab 317:E298-311,

2019.


31

CHAPTERS, EDITORIALS AND INVITED REVIEWS

1. Dorn GW II, Halushka PV. Thromboxane synthetase inhibitors, thromboxane receptor

antagonists, and aspirin in cardiovascular disease. Ration Drug Ther 19:1-7, 1985.

2. Halushka PV, Mais DE, Dorn GW II, Liel N. A role for thromboxane A2 in cardiovascular and

renal diseases? Emory University Journal of Medicine 2:19-32, 1988.

3. Dorn GW II, Hauger DA. Platelet and vascular endothelial cell biology in atherosclerosis.

In Contemporary Management in Internal Medicine. Update on Hemostasis. Boldt DH (ed.)

Churchill Livingstone, New York, 3-40, 1990.

4. Lewis W, Dorn GW II. Cardiac Structure and Function in HIV-Infected Children.

N Engl J Med 328:513-514, 1993.

5. Dorn GW II. Thrombosis and Hemorrhage. Book Review: Circulation 90:(5)2580, 1994.

6. Dorn GW II. Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells.

Inflammation Research, Agents and Actions Supplements 48:42-62, 1997.

7. Walsh RA, Dorn GW II. Growth and hypertrophy of the heart and blood vessels. In Hurst’s

THE HEART, 9th Edition, Chapter 6:155-168, 1997.

8. Dorn GW II. Isolated myocyte mechanics and calcium transients. In Cardiovascular

Physiology in the Genetically Engineered Mouse, Chapter 4:55-68, 1998.

9. Dorn GW II, Brown JH. Gq signaling in cardiac adaptation and maladaptation. Trends

Cardiovasc Med 9:26-34, 1999.

10. Dorn GW II. G proteins in heart disease. Heart Failure Reviews 4:303-310, 1999.

11. Robbins J, Dorn GW II. Listening for hoof beats in heart beats. Nat Med 6:968-970, 2000.

12. Molkentin JD, Dorn GW II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy.

Annu Rev Physiol 63:391-426, 2001.

13. Dorn GW II. Calcineurin inhibition in hypertrophy: Back from the dead! Circulation 104:9-11,

2001.

14. Dorn GW II, Mochly-Rosen D. Intracellular transport mechanisms of signal transducers. Annu

Rev Physiol 64:407-429, 2002.

15. Dorn GW II, Mann, DL. Signaling pathways involved in left ventricular remodeling:

Summation. J Card Fail. 8:S387-S388, 2002.

16. Dorn GW II. Adrenergic pathways and left ventricular remodeling. J Card Fail. 8:S370-S373,

2002.

17. Azhar M, Schultz Jel J, Grupp I, Dorn GW II, Meneton P, Molin DG, Gittenberger-de Groot AC,

Doetschman T. Transforming growth factor beta in cardiovascular development and function.

Cytokine Growth Factor Rev 14:391-407, 2003.

18. Dorn GW II, Robbins J, Sugden PH. Phenotyping hypertrophy: Eschew obfuscation. Circ Res,

92:1171-5, 2003.

19. Dorn GW II and Molkentin JD. Manipulating cardiac contractility in heart failure: Data from

mice and men. Circulation, 109: 150-158, 2004.

20. Dorn GW II and Hahn HS. Genetic Factors in Cardiac Hypertrophy. Ann N.Y. Acad. Sci.

1015:225-237, 2004.

21. Dorn GW II and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J.

Clin. Invest. 115:527-37, 2005.

22. Dorn GW II. Physiological growth and pathological genes in cardiac development and

cardiomyopathy. Trends. Cardiovasc. Medicine. 15:185-9, 2005.

23. Dorn GW II and Wagoner LE. “Adrenergic receptor signaling and cardiac remodeling” in


32

Cardiac Remodeling: Mechanisms and Treatment, Chapter 13:215-240, 2006.


33

CHAPTERS, EDITORIALS AND INVITED REVIEWS (cont.)

24. Dorn GW II. Containing hypertrophy with a PICOT fence. Circ Res, 99:228-30, 2006.

25. Diwan A and Dorn GW II. Decompensation of cardiac hypertrophy: Cellular mechanisms and

novel therapeutic targets. Physiology, 22:56-64, 2007.

26. Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension, 49:962-70,

2007.

27. Dorn GW II. The Gordon Wilson Lecture: Neurohormonal signaling pathways that link cardiac

growth and death. Trans Am Clin Climatol Assoc, 118:137-52, 2007.

28. Dorn GW II. Myocardial Angiogenesis: It’s Absence Makes the Growing Heart Founder.

Cell Metabolism, 5:326-7, 2007.

29. Dorn GW II. Periostin and myocardial repair, regeneration, and recovery. New Engl J Med,

57:1552-4, 2007.

30. Dorn GW II and Diwan A. The rationale for cardiomyocyte resuscitation in myocardial salvage.

J Mol Med, 86:1085-95, 2008.

31. Dorn GW II and Cresci S. The mechanistic imperative for pharmacogenomics.

Pharmacogenomics, 9:801-3, 2008.

32. Dorn GW II and Matkovich SJ. Put your chips on transcriptomics. Circulation, 118:216-8,

2008.

33. Dorn GW II and Liggett SB. Pharmacogenomics of -adrenergic receptors and their accessory

signaling proteins in heart failure. Clin and Translat Sci, 1:255-262, 2008.

34. Dorn GW II and Kirshenbaum LA. Cardiac reanimation: Targeting cardiomyocyte death by

Bnip3 and Bnip3L. Oncogene, 27:S158-167, 2008.

35. Dorn GW II Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular

remodeling. Cardiovasc Res, 81:465-73, 2009.

36. Dorn GW II. Novel pharmacotherapeutics to improve post-infarction ventricular repair,

recovery, and remodeling. Nat Clin Rev Cardiol, 6:283-91, 2009.

37. Dorn GW II. GRK Mythology: G-protein receptor kinases in cardiovascular disease. J Mol

Med, 87:455-63, 2009.

38. Dorn GW II and Cresci S. Genome-wide association studies of coronary artery disease and heart

failure: Where are we going? Pharmacogenomics, 10:213-23, 2009.

39. Dorn GW II and Liggett SB. Mechanisms of pharmacogenomic effects of genetic variation of

the cardiac adrenergic network in heart failure. Mol Pharmacol, 76:466-80, 2009.

40. Dorn GW II. Having a change of heart: reversing the suicidal proclivities of cardiac myocytes.

Trans Am Clin Climatol Assoc 120:189-98, 2009.

41. Dorn GW II. Pharmacogenetic profiling in the treatment of heart disease. Transl Res 154:295-

302, 2009.

42. Condorelli G, Latronico MV, Dorn GW II. microRNAs in heart disease: putative novel

therapeutic targets? Eur Heart J, 31:649-58, 2010.

43. Dorn GW II. Therapeutic potential of microRNAs in heart failure. Curr Cardiol Rep, 12:209-15,

2010.

44. Dorn GW II. Adrenergic signaling polymorphisms and their impact on cardiovascular disease.

Physiological Reviews, 90:1013-62, 2010.

45. Dorn GW II. Refugee receptors switch sides. Science, 327:1586-7, 2010.


34


46. Dorn GW II. Mechanisms of non-apoptotic programmed cell death in diabetes and heart failure.

Cell Cycle, 9:3442-8, 2010.

47. Dorn GW II and Scorrano L. Two close, too close: Sarcoplasmic reticulum-mitochondrial cross-

talk and cardiomyocyte fate. Circ Res, 107:689-699 2010.

48. Dorn GW II. MicroRNAs: Redefining mechanisms in cardiac disease. J Cardiovasc

Pharmacol, 56:589-95, 2010.

49. Diwan A and Dorn GW II. “Molecular Basis for Heart Failure” in Heart Failure, a companion

to Braunwald’s Heart Disease. Chapter 2, 7-31, 2011.

50. Dorn GW II. MicroRNAs in cardiac disease. Transl Res, 157:226-35, 2011.

51. Dorn GW II. Nix Nought Nothing: Fairy tale or real deal. J Mol Cell Cardiol, 51:497-500,2011.

52. Dorn GW II. Genetics of common forms of heart failure. Curr Opin Cardiol 26:204-8, 2011.

53. Dorn GW II. The Genomic architecture of sporadic heart failure. Circ Res, 108:1270-83, 2011.

54. Cappola TP and Dorn GW II. Clinical considerations of heritable factors in common heart

failure. Circ Cardiovasc Gen, 4:701-9, 2011.

55. Dorn GW II and Kitsis RN. “Programmed Cardiomyocyte Death in Heart Disease” in Muscle:

Fundamental Biology and Mechanisms of Disease. Chapter 31, 423-446, 2012.

56. Dorn GW II. Decoding the cardiac message. Circ Res, 110:755-63, 2012.

57. Dorn GW II. Resolving a catch-22 in cardiac gene regulation. Circulation, 125:2695-7, 2012.

58. Dorn GW II. Inflame on! Mitochondrial escape provokes cytokine storms that doom the heart.

Circ Res, 111:271-273, 2012.

59. Dorn GW II. Mitochondrial dynamics in heart disease. Biochim Biophys Acta, 1833:233-41,

2013.

60. Dorn GW II and Maack C. SR and mitochondria: Calcium cross-talk between kissing cousins.

J Mol Cell Cardiol, 55:42-9, 2013.

61. Dorn GW II. Molecular mechanisms that differentiate apoptosis from programmed necrosis.

Toxicol Pathol, 41:227-34, 2013.

62. Westenbrink BD and Dorn GW II. Imaging the cardiac diet. Eur J Heart Fail, 15:123-4, 2013.

63. Dorn GW II. “Molecular Signaling Networks Underlying Cardiac Hypertrophy and Failure” in

Heart Failure, Marc J Semigran and Jordan T Shin editors. Second edition, Chapter 3, 31-42,

2013.

64. Dorn GW II. Shared genetic risk for sclerosis of valves and vessels. N Engl J Med, 368:569-70,

2013.

65. Dorn GW II. MicroRNAs and the butterfly effect. Cell Cycle 12:707-8, 2013.

66. Dorn GW II. Mitochondrial dynamism and cardiac fate: a personal perspective. Circ J,

77:1370-9, 2013.

67. Dorn GW II miR-34a and the cardiomyopathy of senescence: SALT PNUTS, SALT PNUTS!

Cell Metab, 17:629-30, 2013.

68. Dorn GW II and Matkovich SJ. Ménage à Trois: Intimate relationship between a microRNA,

long noncoding RNA and mRNA. Circ Res, 114:1362-5, 2014.

69. Dorn GW II. LIPCAR: A mitochondrial lnc in the noncoding RNA chain. Circ Res, 114:1548-

50, 2014.

70. Dorn GW II and McNally EM. Two Strikes and You’re Out: Gene–Gene Mutation Interactions

in HCM. Circ Res, 115:208-210, 2014.


35


71. Dorn GW II and Kitsis RN. The mitochondrial dynamism-mitophagy-cell death interactome:

Multiple roles performed by members of a mitochondrial molecular ensemble. Circ Res,

116:167-182, 2015.

72. Dorn GW II, Song M, Walsh K. Functional implications of mitofusin 2-mediated mitochondrial-

SR tethering. J Mol Cell Cardiol, 78C:123-128, 2015.

73. Dorn GW II and Matkovich SJ. Epitranscriptional regulation of cardiovascular development and

disease. J Physiol, 593:1799-808, 2015.

74. Dorn GW II. Gone fission…. Diverse consequences of cardiac Drp1 deficiency. Circ Res,

116:225-8, 2015.

75. Song M and Dorn GW II. Mitoconfusion: Non-canonical functioning of dynamism factors in

static mitochondria of the heart. Cell Metab, 21:195-205, 2015.

76. Dorn GW II. Cardiac regeneration – Alchemy, science, and a wee bit of magic? J Mol Cell

Cardiol 81C:10-11, 2015.

77. Matkovich SJ and Dorn GW II. Deep sequencing of cardiac microRNA-mRNA interactomes in

clinical and experimental cardiomyopathy. Methods Mol Biol, 1299:27-49, 2015.

78. Dorn GW II. Mitochondrial dynamism and heart disease: changing shape and shaping change.

EMBO Mol Med, 7:865-77, 2015.

79. Shirihai O, Song M, Dorn GW II. How mitochondrial dynamism orchestrates mitophagy. Circ

Res, 116:1835-49, 2015.

80. Dorn GW II. Great Expectations: MicroRNA-30d and cardiac resynchronization therapy.

Circulation, 131:2172-5, 2015.

81. Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang CP, Dorn GW II, Thum

T, Heymans S. Long noncoding RNAs in cardiac development and ageing. Nat Rev Cardiol,

12:346-51, 2015.

82. Dorn GW II, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and

diseased heart. Genes Dev, 29:1981-91, 2015.

83. Dorn GW II. Parkin-dependent mitophagy in the heart. J Mol Cell Cardiol, 95:42-9, 2016.

84. Dorn GW II. Jurassic PARK2: You eat your mitochondria, and you are what your mitochondria

eat. Autophagy, 12:610-11, 2016.

85. Dorn GW II. Mitochondrial fission/fusion and cardiomyopathy. Curr Opin Genet Develop,

38:38-44, 2016.

86. Dorn GW II. Central Parkin: The evolving role of Parkin in the heart. Biochim Biophys Acta

Bioenergetics, 1857:1307-12, 2016.

87. Dorn GW II. Tension-time integrals and genetic cardiomyopathy: The force is with you. Cell,

165:1049-50, 2016.

88. Dorn GW II. Canon Fodder – A case for contrarian science. Circ Res 119:584-6, 2016.

89. Matkovich SJ, Dorn GW II. Feed My Heart or Eat It: miR-22 Decides. J Am Coll Cardiol,

68:1572-4, 2016.

90. Naon D, Zaninello M, Giacomello M, Varanita T, Grespi F, Lakshminaranayan S, Serafini A,

Semenzato M, Herkenne S, Hernández-Alvarez MI, Zorzano A, De Stefani D, Dorn GW II,

Scorrano L. Reply to Filadi et al.: Does mitofusin 2 tether or separate endoplasmic reticulum and

mitochondria? Proc Natl Acad Sci USA 114:E2268-9, 2017.

91. Yanamandala M, Zhu W, Garry DJ, Kamp TJ, Hare JH, Jun H-W, Yoon Y-S, Bursac N, Prabhu

SD, Dorn GW II, Boli R, Kitsis RN, Zhang J. Overcoming the roadblocks to cardiac cell therapy


36

using tissue engineering. J Am Coll Cardiol 70:766-75, 2017.

92. Dorn GW II. Cardiac-specific research platforms engender novel insights into mitochondrial

dynamism. Current Opin Physiol. 3:110-115, 2018.

93. Dorn GW II. Evolving concepts of mitochondrial dynamics. Annu Rev Physiol. 81:1-17, 2019.

94. Gustafsson AB and Dorn GW II. Evolving and expanding roles of mitophagy as a homeostatic

and pathogenic process. Physiol Rev. 99:853-892, 2019.

Documents

CURRICULUM VITAE Gerald W. Dorn II, M.D